OBJECTIVE: To evaluate the wound healing of recipient and donor sites following keratinized mucosa augmentation (KMA) around implants in reconstructed jaw areas and to compare these outcomes with gingival grafts in native jawbone, so as to provide clinical guidance for postoperative maintenance, and to investigate the impact of clinical experience on the evaluation of KMA postoperative healing through subgroup comparisons. METHODS: This study included patients who underwent resection of maxillofacial tumors, fibular or iliac flap reconstruction, and implant placement at Peking University Dental Hospital from October 2020 to April 2023. Three months post-implant placement, the patients were referred for KMA procedures. Clinical photographs of the reconstructed area were taken preoperatively, immediately postoperatively, and 3 weeks and 3 months post-surgery. Additionally, photographs of the palatal donor site were obtained preoperatively and 3 weeks later. Wound healing was assessed by four junior and three senior clinicians utilizing the early healing index (EHI), early wound healing score (EHS), and pink esthetic score (PES).And senior clinicians evaluated the healing effect compared with gingival transplantation on natural jawbone using a 10-point scale. RESULTS: A total of 26 patients with jawbone reconstruction were included, with an average age of (34.2±10.2) years, 11 males (42.3%) and 15 females (57.7%). Among them, 13 cases (50.0%) underwent fibula flap reconstruction, and 13 cases (50.0%) underwent iliac flap reconstruction. The average number of implants per patient was 3.2±0.7. In the recipient area, 3 weeks postoperatively, the EHS was 7.0 (4.0, 9.0), with sub-item scores as follows: Clinical signs of re-epithelialization (CSR) 6.0 (3.0, 6.0), clinical signs of haemostasis (CSH) 1.5 (1.0, 2.0), and clinical signs of inflammation (CSI) 1.0 (0.0, 1.0), indicating that the average appearance of the wound in the recipient area was characterized by generally well-approximated wound edges with minimal fibrin lines and mild erythema and swelling. The EHI for the recipient area was 2.0 (1.5, 2.5), suggesting that the incision was mostly closed with some fibrin lines 3 weeks postoperatively. The long-term healing evaluation system, PES, was 2.5 (2.0, 3.0), with sub-scores for color [1.0 (1.0, 1.5)] and texture [1.5 (1.0, 2.0)], which were slightly different from the reference values.In the palatal donor area, 3 weeks postoperatively, the EHI score was lower at 1.3 (1.0, 2.5), while the EHS score was higher at 8.5 (6.0, 10.0), indicating better soft tissue healing in the donor area compared with the recipient area. Among the clinicians with different levels of experience, the assessment of wound healing revealed that except for the CSI sub-item, where the junior group scored higher than the senior group, all other sub-items showed significantly higher scores in the senior group compared with the junior group. In the EHS evaluation system, the CSH sub-item demonstrated no significant differences between the groups with varying levels of experience. Experienced clinicians' evaluation outcomes of healing effect compared with gum graft on natural alveolar bone was 8.5 (7.5, 9.5), showing high consistency [intraclass correlation coefficient (ICC): 0.892; 95% confidence interval (CI): 0.791－0.949], suggesting slightly suboptimal healing results after KMA surgery. CONCLUSION The healing process following KMA in the context of jawbone reconstruction is relatively protracted, emphasizing the necessity for comprehensive postoperative management. Moreover, clinician experience plays a significant role in the assessment of wound healing outcomes for KMA in maxillofacial reconstruction.
Humans ; Wound Healing ; Adult ; Male ; Female ; Gingiva/transplantation* ; Plastic Surgery Procedures/methods* ; Middle Aged ; Surgical Flaps ; Keratins

Humans ; Gingival Recession/surgery* ; Gingivoplasty/methods* ; Connective Tissue/transplantation* ; Treatment Outcome ; Gingiva/transplantation* ; Tooth Root

We report a case of 13 years old male patient. He was diagnosed as glycogen storage disease Ib at 6 month age, and received cadaver donor liver transplantation at 2 years and 4 months. He underwent immunosuppression for 9 years with several immunosuppressants including tacrolimus. Then he visited hospital for gum swelling and showed multiple malignancy suspicious lesions at nasal cavity, maxilla, mandibula, frontal bone, temporal bone, C1 and C2 spines, and several submandibular lymph nodes at radiologic study. Biopsy was done at oral cavity lesion, and histologically diagnosed as diffuse large B-cell lymphoma. The tissue specimen showed positivity in Epstein-Barr virus polymerase chain reaction (PCR). After diagnosis, the patient stopped all immunosuppressive agents and received 9 cycles of CHOP (cyclophosphamide, adriamycin, vincristine and prenisolone) chemotherapy for 8 months, then the patient achieved radiologic remission state, and being well without any signs of recurrence for two years of follow up.
Biopsy ; Cadaver ; Child ; Doxorubicin ; Follow-Up Studies ; Frontal Bone ; Gingiva ; Glycogen Storage Disease ; Glycogen Storage Disease Type I ; Herpesvirus 4, Human ; Humans ; Immunosuppression ; Immunosuppressive Agents ; Liver ; Liver Transplantation ; Lymph Nodes ; Lymphoma ; Lymphoma, B-Cell ; Male ; Maxilla ; Mouth ; Nasal Cavity ; Polymerase Chain Reaction ; Recurrence ; Spine ; Tacrolimus ; Temporal Bone ; Tissue Donors ; Transplants ; Vincristine

PURPOSE: In advanced case of periodontitis, surgical treatment without bone contouring may result in residual pockets inaccessible to proper cleaning during post-treatment maintenance. This problem can be avoided or reduced by applying guided tissue regeneration. MATERIALS AND METHODS: All of 3 patients had deep periodontal pocket depth and bleeding on probing, and radiograph revealed osseous defect, so we planned guided tissue regeneration using resorbable membrane with or without xenograft. RESULT: 6 months later, periodontal pocket depth and bleeding on probing was improved and gingiva was stable. CONCLUSION: Guided tissue regeneration using resorbable membrane with or without xenograft in osseous defect is predictable.
Gingiva ; Guided Tissue Regeneration ; Hemorrhage ; Humans ; Membranes ; Periodontal Pocket ; Periodontitis ; Transplantation, Heterologous

PURPOSE: The calcineurin inhibitors, tacrolimus and cyclosporine, have been used as primary immunosuppressant in renal transplantation. Tacrolimus has been shown to be an effective alternative to cyclosporine for the prevention of acute rejection but the two drugs are different in side-effect profile. This retrospective study compares the efficacy and safety of tacrolimus-based versus cyclosporine-based immunosuppression in patients receiving kidney transplantation. METHODS: There were 177 consecutive recipients of kidney graft; 90 received cyclosporine-based immunosuppression therapy, and 87 received tacrolimus-based immunosuppression. Graft and patient survival rate, incidence of acute rejection and side effects were compared. RESULTS: The 3-year graft survival rate of cyclosporine and tacrolimus was similar (93.0% vs. 91.4%). The incidence of acute rejection was significantly less in the tacrolimus group compared with the cyclosporine group (10.3% vs. 31.1%, P<0.05). Incidence of impaired renal function, gastrointestinal disorder, tremor, hypertension and hyperkalemia were comparable in both treatment groups. Higher incidence of posttransplant diabetes, allopecia, abdominal pain and headache was reported in the tacrolimus group, whereas that of hypercholesterolmeia, hirsuitism, and gum hyperplasia was more frequent with cyclosporine group. CONCLUSION: Tacrolimus is as effective as cyclosporine in patient and graft survival in kidney transplantation. Due to different side-effect profiles, it is needed to develop individualized immunosuppressive strategies in renal transplant recipients.
Abdominal Pain ; Calcineurin ; Cyclosporine* ; Gingiva ; Graft Survival ; Headache ; Humans ; Hyperkalemia ; Hyperplasia ; Hypertension ; Immunosuppression ; Incidence ; Kidney Transplantation* ; Kidney* ; Retrospective Studies ; Survival Rate ; Tacrolimus* ; Transplantation ; Transplants ; Tremor

PURPOSE: Tacrolimus (FK-506) represents a major advance in the prevention of rejection following solid organ transplantation. Previous clinical trials in Japan, Europe, and the US suggest that tacrolimus is an effective primary immunosuppressive agent in kidney transplantation. This prospective, non-randomized single center study was done to confirmed the efficacy of tacrolimus in kidney transplantation. METHODS: A total of 50 renal transplant recipients who followed-up at least one year after transplantation was included in this study. Thirty six cases (72%) recived triple drug therapy consists of tacrolimus, mycophenolate mofetil (MMF), and low dose steroid. RESULTS: The overall incidence of acute rejection was 10%, all episodes of rejection were treated effectively with steroid pulse therapy. The incidence of treatment failure was six percent. One and two year graft survival were 98% and 96%, respectively. Adverse effects of tacrolimus therapy included tremor of the hand (56%), diarrhea (34%), alopecia (26%), hyperkalemia (22%), nephrotoxicity (18%), post transplant diabetes mellitus (14%), hypertension (14%), and hypercholesterolemia (10%). However, the incidence of gum hypertrophy and hirsutism were 6% and 2%, respectively. CONCLUSION: This short-term study indicates that tacrolimus appears to provide safe and effective primary immunosuppression in kidney transplantation.
Alopecia ; Diabetes Mellitus ; Diarrhea ; Drug Therapy ; Europe ; Gingiva ; Graft Survival ; Hand ; Hirsutism ; Hypercholesterolemia ; Hyperkalemia ; Hypertension ; Hypertrophy ; Immunosuppression* ; Incidence ; Japan ; Kidney Transplantation* ; Organ Transplantation ; Prospective Studies ; Tacrolimus* ; Transplantation ; Transplants ; Treatment Failure ; Tremor

Adhesives ; Burns ; Calcium Chloride ; Cicatrix ; Cicatrix, Hypertrophic ; Collagen ; Factor XIII ; Fibrin Tissue Adhesive ; Fibrin ; Fibrinogen ; Follow-Up Studies ; Gingiva ; Hemorrhage ; Humans ; Mouth ; Nose ; Polymers ; Skin Transplantation ; Skin ; Surgery, Oral ; Sutures ; Thrombin ; Tissue Donors ; Transplants ; Wound Healing